肿瘤细胞治疗研究
英文原题：Application of oncolytic virus in tumor therapy.
溶瘤病毒（OVs）能选择性杀伤肿瘤细胞而不影响正常细胞，同时激活患者的固有免疫和适应性免疫系统。
溶瘤病毒（OVs）能够选择性杀伤肿瘤细胞而不影响正常细胞，同时激活患者的固有免疫和适应性免疫系统。因此，它们被认为是一种安全有效治疗癌症的有前景的手段。近年来，一些基因工程化OVs已被开发出来，通过表达特定的免疫调节因子，进一步增强机体抗肿瘤免疫，从而提高肿瘤清除效果。此外，OVs与其他免疫疗法的联合治疗已在临床中应用。尽管关于这一热点课题已有许多研究，但尚缺乏一篇全面综述来阐明OVs清除肿瘤的机制以及如何改造工程化OVs以进一步增强其抗肿瘤效果。在本研究中，我们综述了OVs中免疫调节因子的机制。此外，我们还综述了OVs与放疗及CAR-T或TCR-T细胞治疗等其他疗法联合应用的情况。该综述有助于进一步推广OV在癌症治疗中的应用。
Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well as activate the innate and adaptive immune systems in patients. Thus, they have been considered as a promising measure for safe and effective cancer treatment. Recently, a few genetically engineered OVs have been developed to further improve the effect of tumor elimination by expressing specific immune regulatory factors and thus enhance the body's antitumor immunity. In addition, the combined therapies of OVs and other immunotherapies have been applied in clinical. Although there are many studies on this hot topic, a comprehensive review is missing on illustrating the mechanisms of tumor clearance by OVs and how to modify engineered OVs to further enhance their antitumor effects. In this study, we provided a review on the mechanisms of immune regulatory factors in OVs. In addition, we reviewed the combined therapies of OVs with other therapies including radiotherapy and CAR-T or TCR-T cell therapy. The review is useful in further generalize the usage of OV in cancer treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
